证券代码：688161 券简称：威高骨科 公告编号：2024-051 山东威高骨科材料股份有限公司 第三届董事会第十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 山东威高骨科材料股份有限公司（以下简称"公司"）第三届董事会第十二 次会议于 2024 年 10 月 29 日以现场及通讯相结合的方式召开。本次会议应出席 董事 9 人，实际出席董事 9 人，会议由董事长陈敏女士主持，本次董事会会议的 召集和召开程序符合有关法律、行政法规、部门规章、规范性文件和《公司章程》 的规定，会议决议合法、有效。 二、董事会会议审议情况 1、审议通过《关于公司<2024 年第三季度报告>的议案》 公司董事会认为：公司《2024 年第三季度报告》的编制和审议程序符合法 律、法规、《公司章程》和公司内部管理制度的各项规定；公司《2024 年第三季 度报告》的内容与格式符合中国证券监督管理委员会和上海证券交易所的各项规 定，能够公允地反映公司报告期内的财务状况和经营成果。董事会及全体董事保 证公司《2024 ...

山东威高骨科材料股份有限公司 相关事项的独立意见 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所 科创板股票上市规则(2024年4月修订)》及《公司章程》等的相关规定，作为 山东威高骨科材料股份有限公司(以下简称"公司")的独立董事,本着谨慎性 的原则,基于独立判断立场,对公司第三届董事会第十二次会议相关事项发表独 立意见如下: 一、《关于拟聘请会计师事务所的议案》的独立意见 经审议,我们认为:致同会计师事务所(特殊普通合伙)具备证券相关业务 资格,具有多年为上市公司提供审计服务的经验,能够为公司提供真实、准确、 客观、公正的审计服务,满足公司 2024 年度财务审计及内部控制审计工作要求。 公司本次聘请会计师事务所的审议程序符合法律、法规和《公司章程》的有关规 定,不存在损害公司及全体股东,特别是中小股东利益的情形。 综上,我们一致同意聘任致同会计师事务所（特殊普通合伙）为公司 2024 年度财务报告和内部控制审计机构，并同意将该议案提交公司 2024 年第三次临 时股东大会审议。 二、《关于进行 2024年三季度中期分红的议案》的独立意见 为进一步提高分红频次，增强投资者回报水平，公 ...

Revenue and Profit Performance - Revenue for the third quarter was RMB 332.74 million, a 20.06% increase compared to the same period last year[2] - Net profit attributable to shareholders of the listed company for the third quarter was RMB 71.16 million, a 594.19% increase year-over-year[2] - The company achieved a revenue of RMB 1,083.28 million in the first three quarters, a year-on-year increase of 0.07%, and a net profit attributable to shareholders of RMB 164.29 million, a year-on-year increase of 34.66%[11] - In the third quarter, the company achieved a revenue of RMB 332.74 million, a year-on-year increase of 20.06%, and a net profit attributable to shareholders of RMB 71.16 million, a year-on-year increase of 594.19%[11] - Total operating revenue for the first three quarters of 2024 was RMB 1,083,278,467.47, a slight increase from RMB 1,082,526,944.91 in the same period of 2023[22] - Net profit attributable to the parent company's shareholders in the first three quarters of 2024 was RMB 164,293,158.99, compared to RMB 122,008,305.50 in the same period of 2023, representing a growth of 34.7%[23] - The increase in revenue was primarily due to higher sales volume compared to the same period last year[6] Earnings Per Share and Return on Equity - Basic earnings per share for the third quarter were RMB 0.18, a 500% increase compared to the same period last year[2] - Diluted earnings per share for the third quarter were RMB 0.18, a 500% increase compared to the same period last year[3] - Weighted average return on equity for the third quarter was 1.82%, an increase of 1.56 percentage points compared to the same period last year[3] - Basic earnings per share for the first three quarters of 2024 were RMB 0.41, up from RMB 0.31 in the same period of 2023, reflecting a 32.3% increase[24] R&D and Sales Expenses - R&D investment for the third quarter was RMB 27.51 million, accounting for 8.27% of revenue, a decrease of 0.72 percentage points compared to the same period last year[3] - R&D expenses for the first three quarters of 2024 increased to RMB 91,157,022.54, up from RMB 86,638,389.02 in the same period of 2023, reflecting a 5.2% increase[22] - The company's sales expense ratio decreased by 9 percentage points year-on-year due to optimized marketing organization and personnel structure, channel integration, and refined expense management[12] - Sales expenses decreased to RMB 371,892,305.06 in the first three quarters of 2024, down from RMB 468,100,649.76 in the same period of 2023, a reduction of 20.6%[22] Product Line Performance - The spine product line achieved sales revenue of RMB 331 million in the first three quarters, a year-on-year decrease of 16.23%, with sales volume increasing by 36.17%[12] - The trauma product line achieved sales revenue of RMB 188 million in the first three quarters, a year-on-year increase of 16.25%, with sales volume increasing by 18.45%[12] - The joint product line achieved sales revenue of RMB 300 million in the first three quarters, a year-on-year increase of 23.12%, with sales volume increasing by over 27.37%[13] - The sports medicine product line achieved sales revenue of RMB 28.54 million in the first three quarters, a year-on-year increase of over 11 times[14] - The tissue repair product line achieved sales revenue of approximately RMB 130 million in the first three quarters, a year-on-year increase of 20.49%, with sales volume increasing by 65.74%[14] - The company's quantum medical revenue reached approximately 24 million yuan, a year-on-year increase of over 3 times[15] Assets and Liabilities - Total assets at the end of the reporting period were RMB 5.02 billion, a 1.56% decrease compared to the end of the previous year[3] - The company's total assets amounted to 5,017,260,766.83 yuan, with current assets totaling 4,241,592,416.03 yuan[19] - The company's total liabilities were 1,094,005,081.86 yuan, with current liabilities accounting for 967,428,423.95 yuan[20] - The company's fixed assets were valued at 441,498,720.68 yuan, showing a decrease from the previous period[19] - The company's inventory was valued at 743,556,501.84 yuan, slightly decreasing from the previous period[19] - Total equity attributable to the parent company's shareholders as of the end of Q3 2024 was RMB 3,913,925,667.34, compared to RMB 3,868,918,255.96 at the end of Q3 2023, showing a 1.2% increase[21] - The company's total liabilities and equity as of the end of Q3 2024 were RMB 5,017,260,766.83, slightly lower than RMB 5,096,573,977.62 at the end of Q3 2023, a decrease of 1.6%[21] Cash Flow and Financial Activities - Net cash flow from operating activities for the period from the beginning of the year to the end of the reporting period was RMB 189.84 million, a 103.67% increase year-over-year[2] - Operating cash flow increased to 189.84 million yuan, up 103.7% year-over-year from 93.21 million yuan[26] - Investment cash inflow totaled 859.48 million yuan, with 840 million yuan from investment recoveries[26] - Investment cash outflow reached 864.66 million yuan, including 852 million yuan for new investments[26] - Financing cash outflow was 87.51 million yuan, with 47.99 million yuan allocated for dividend and interest payments[27] - Net cash and cash equivalents increased by 105.71 million yuan, compared to a decrease of 925.03 million yuan in the same period last year[27] - End-of-period cash and cash equivalents stood at 1.92 billion yuan, up from 1.78 billion yuan at the end of the previous period[27] - Tax refunds received amounted to 2.29 million yuan, a decrease from 14.97 million yuan in the previous year[26] - Cash received from other operating activities was 23.17 million yuan, down from 90.26 million yuan year-over-year[26] - Cash paid for employee compensation was 250.07 million yuan, slightly lower than the 254.44 million yuan in the previous year[26] - Cash paid for taxes and fees decreased to 90.44 million yuan from 225.29 million yuan year-over-year[26] - Cash received from sales of goods and services in the first three quarters of 2024 was RMB 1,244,264,410.31, a decrease from RMB 1,349,627,802.79 in the same period of 2023, representing a 7.8% decline[25] Government Subsidies and Other Income - Government subsidies included in current profits amounted to RMB 1.52 million for the third quarter[4] Overseas Business and Trade - The company's overseas trade grew by 52% year-on-year, with rapid expansion in overseas business[17] Product Approvals and Innovations - The company's "plasma surgery equipment" was approved by the National Medical Products Administration, enriching the minimally invasive treatment product line[16] - The company's "one-time use annulus suture device" was approved, enhancing post-surgery stability and reducing recurrence rates[16] - The company's "occipital-cervical-thoracic spine posterior fixation system" was approved, offering flexible configurations and superior biomechanical performance[15] Production and Operational Efficiency - The company optimized production capacity and improved manufacturing efficiency through scientific equipment allocation[17] Comprehensive Income - Total comprehensive income for the first three quarters of 2024 was RMB 168,426,611.66, compared to RMB 121,877,124.55 in the same period of 2023, showing a 38.2% growth[23]

证券代码：688161 证券简称：威高骨科 公告编号：2024-049 为积极响应监管号召、进一步提高投资者回报水平，推动一年多次分红，公 司根据中国证监会《上市公司监管指引第 3 号—上市公司现金分红》《上海证券 交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号—规范运作》等相关法律法规及《公司章程》的规定，结合公司实际情况拟 定 2024 年第二次中期分红方案，具体内容如下： 一、第二次中期分红的具体方案 山东威高骨科材料股份有限公司 关于进行 2024 年第二次中期分红的公告 ●分配比例：每 10 股派发现金红利 0.50 元（含税），不进行资本公积转增 股本，不送红股。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ●本次分红以实施权益分派股权登记日登记的总股本扣减山东威高骨科材 料股份有限公司（以下简称"公司"）回购专用证券账户中的股份为基数，具体 日期将在权益分派实施公告中明确。本次分红方案涉及差异化分红。 重要内容提示： ●在实施权益分派的股权登记日前公司总股本扣减回购专用证券账户 ...

证券代码：688161 证券简称：威高骨科 公告编号：2024-052 山东威高骨科材料股份有限公司 第三届监事会第十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 山东威高骨科材料股份有限公司（以下简称"公司"）第三届监事会第十次 会议于 2024 年 10 月 29 日以现场方式召开。本次监事会会议通知及会议材料已 于 2024 年 10 月 18 日向公司全体监事发出。本次会议由监事会主席陈柔姿女士 主持，会议应出席监事 3 人，实际出席监事 3 人。会议的召集和召开程序符合《中 华人民共和国公司法》等法律、法规、部门规章以及《山东威高骨科材料股份有 限公司章程》（以下简称"《公司章程》"）的有关规定，会议决议合法、有效。 具体内容详见公司于上海证券交易所网站（www.sse.com.cn）披露的《2024 年第三季度报告》。 2、审议通过《关于公司拟聘请会计师事务所的议案》 监事会认为：公司拟聘请会计师事务所的理由恰当、程序合规，致同会计师 事务所（特殊普通合伙）具备会计师事务所 ...

证券代码：688161 证券简称：威高骨科 公告编号：2024-048 山东威高骨科材料股份有限公司关于 拟聘请会计师事务所的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 变更会计师事务所的简要原因及前任会计师的异议情况：综合考虑公司 业务发展、审计工作需求等情况，为保证公司审计工作的独立性、客观性，公司 拟聘请致同会计师事务所（特殊普通合伙）为公司 2024 年度财务报告和内部控 制审计机构。公司已就拟变更会计师事务所的相关情况与大华会计师事务所（特 殊普通合伙）进行充分沟通，其对变更事项无异议。 机构名称：致同会计师事务所（特殊普通合伙） 成立日期：2011年12月22日 组织形式：特殊普通合伙 注册地址：北京市朝阳区建国门外大街22号赛特广场五层 首席合伙人：李惠琦 执业证书颁发单位及序号：北京市财政局NO0014469 2、人员信息 2023年度末合伙人数量：225人 一、拟聘任会计师事务所的基本情况 （一）机构信息 1、基本信息 2023年度末注册会计师人数：1,364人 2023年度末签署 ...

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024 年第三次临时股东大会 证券代码：688161 证券简称：威高骨科 公告编号：2024-050 山东威高骨科材料股份有限公司 关于召开 2024 年第三次临时股东大会的通知 召开地点：山东威高骨科材料股份有限公司会议室（威海市旅游度假区香江 街 26 号） （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 11 月 20 日 至 2024 年 11 月 20 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2024年11月20日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2024 年 1 ...

证券代码：688161 证券简称：威高骨科 公告编号：2024-047 山东威高骨科材料股份有限公司 2024 年半年度权益分派实施 公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股现金红利 0.07 元 相关日期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2024/10/24 | 2024/10/25 | 2024/10/25 | 一、 通过分配方案的股东大会届次和日期 经公司 2024 年 4 月 29 日召开的 2023 年年度股东大会授权董事会在符合利润 分配的条件下制定具体的 2024 年上半年利润分配方案，公司于 2024 年 8 月 27 日 召开了第三届董事会第十一次会议，审议通过本次利润分配方案。 二、 分配方案 1. 发放年度：2024 年半年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 （山东威高骨科 ...

华泰联合证券有限责任公司 关于山东威高骨科材料股份有限公司 2024 年半年度持续督导跟踪报告 保荐机构名称：华泰联合证券有限责任公司 被保荐公司简称：威高骨科 保荐代表人姓名：唐澍 联系电话：025-83387919 保荐代表人姓名：唐逸凡 联系电话：025-83387720 根据《证券法》《证券发行上市保荐业务管理办法》和《上海证券交易所科 创板股票上市规则》等有关法律、法规的规定，华泰联合证券有限责任公司（以 下简称"华泰联合证券"或"保荐机构"）作为山东威高骨科材料股份有限公司 （以下简称"威高骨科"、"公司"或"发行人"）首次公开发行股票的保荐机 构，对威高骨科进行持续督导，并出具本持续督导跟踪报告： 一、保荐机构和保荐代表人发现的问题及整改情况 无。 二、重大风险事项 （一）高新科技、先进的治疗理念进入并影响现有主营产品线的风险 公司产品线全面涵盖脊柱类、创伤类、关节类及运动医学等骨科植入医疗器 械领域，且拥有装备先进的机加工产业园，但是来自各领域的科技及技术突破， 例如 AI 技术、机器人技术、新材料、生命科学等，可能会对现有的主营产品线 和机加工方式造成一定的冲击；先进的治疗理念和手术方式可能 ...

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 23.56 CNY based on a 38 times price-to-earnings ratio for 2024 [2][5]. Core Insights - The company's performance is showing a significant improvement, with a recovery in revenue and profit margins expected to continue in the second half of the year [1][2]. - The impact of centralized procurement is gradually diminishing, leading to improved operational metrics across major product lines [1]. - The company has successfully increased its market share and sales volume in key segments, including spinal, trauma, and joint products [1]. Financial Summary - In H1 2024, the company achieved revenue of 751 million CNY, a year-on-year increase of 6.8%, while net profit attributable to shareholders was 93 million CNY, down 16.7% year-on-year [1]. - For Q2 2024, revenue reached 403 million CNY, a year-on-year decrease of 3.1% but a quarter-on-quarter increase of 15.7%, with net profit of 58 million CNY, reflecting a year-on-year increase of 230.5% and a quarter-on-quarter increase of 66.8% [1]. - The company's operating cash flow for H1 2024 was 145 million CNY, a significant increase of 148.5% year-on-year, primarily due to tax refunds and reduced tax payments [1]. Product Line Performance - The spinal product line generated 220 million CNY in revenue in H1 2024, with Q2 revenue increasing by 12% quarter-on-quarter [1]. - The trauma product line achieved 120 million CNY in revenue, with Q2 revenue up 33% quarter-on-quarter [1]. - The joint product line saw revenue of 230 million CNY in H1 2024, with a year-on-year increase in surgical volume of 21% and sales volume of 22% [1]. Profitability Metrics - The company's gross margin for H1 2024 was 64.1%, down 7.2 percentage points year-on-year, while the net margin was 12.8%, down 1.0 percentage point year-on-year [1]. - In Q2 2024, the gross margin improved to 68.1%, up 8.6 percentage points quarter-on-quarter, and the net margin increased to 15.0%, up 4.7 percentage points quarter-on-quarter [1].